Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas
The purpose of this study is to determine the Everolimus aim response in children and adolescents with refractory or relapsed Rhabdomyosarcoma and other soft tissue sarcomas
Refractory or Relapsed RMS and Soft Tissue Sarcomas
DRUG: Everolimus
Determine the Everolimus aim response in children and adolescents with refractory and relapsed Rhabdomyosarcoma and other soft tissue sarcomas, Up to 2 years
Define Everolimus toxicity in this population, Up to 2 years
The purpose of this study is to determine the Everolimus aim response in children and adolescents with refractory or relapsed Rhabdomyosarcoma and other soft tissue sarcomas